Previous studies have suggested that jumonji AT-rich interactive domain 1B (JARID1B)

Previous studies have suggested that jumonji AT-rich interactive domain 1B (JARID1B) plays an important role in the genesis of some types of cancer, and it is therefore considered to be an important drug target protein. higher buy 552309-42-9 JARID1B expression in patients with glioma was associated with a poorer prognosis. The overexpression of JARID1B stimulated the proliferation and migration of glioma cells as well as sphere formation, whereas suppressing the expression of JARID1B produced opposite effects. The overexpression of JARID1B increased the tumorigenicity of glioma cells in a nude mouse xenograft model of glioma. Moreover, the activation of phosphorylated (p-)Smad2 contributes to JARID1B-induced oncogenic activities. These findings suggest that JARID1B is involved in the pathogenesis of glioma, and that the downregulation of JARID1B in glioma cells may be a therapeutic target for the treatment of patients with glioma. with slight modifications (14). Briefly, single-cell suspensions were plated in ultralow attachment 96-well buy 552309-42-9 plates (Costar) at different buy 552309-42-9 densities of viable cells. The cells were grown in a serum-free mammary epithelial growth medium (MEGM), supplemented with 1:50 B27 (Invitrogen), 20 ng/ml epidermal growth factor (EGF), 20 ng/ml basic fibroblast growth factor (bFGF) (BD Biosciences) and 10 … Suppression of JARID1B inhibits the proliferation, migration and invasiveness of glioma cells as well as sphere formation To examine the effect of buy 552309-42-9 JARID1B knockdown on the proliferation, migration and invasiveness of glioma cells as well as sphere formation, the SW1783 human glioma cell line, a highly tumorigenic cell line commonly used in glioma research, was transfected with pSuper-shJARID1B or the control (pSuper). As shown by western blot analysis (Fig. 6A), JARID1B protein expression levels were significantly suppressed in the cells transfected with pSuper-shJARID1B. The results of the MTT assay also revealed that the suppression of JARID1B was associated with a decrease in cell proliferation (Fig. 6B). The sphere formation assay showed that the suppression of JARID1B significantly decreased the number of spheres formed (Fig. 6C). As indicated by the Transwell assay and Matrigel assay, knockdown of JARID1B expression significantly inhibited the migration and invasiveness of glioma cell (Fig. 6D). These buy 552309-42-9 results provide further evidence to indicate that JARID1B is involved in the proliferation and migration of glioma cells. Figure 6 Downregulation of jumonji AT-rich interactive domain 1B (JARID1B) reduces tumorigenesis in glioma carcinogenesis, a xenograft model of glioma was established by implanting U251-pBabe and U251-pBabe-JARID1B cells subcutaneously into the right flanks of nude mice. The tumor size was continuously monitored weekly. The tumors of the mice injected with U251-pBabe-JARID1B cells were significantly larger than those of the control mice injected with U251-pBabe cells 2 weeks after Rabbit Polyclonal to AurB/C tumor cell injection (Fig. 7A). The average weight of tumors from the mice injected with U251-pBabe-JARID1B cells was 5 g while that of the control mice injected with U251-pBabe cells was 2 g (Fig. 7B). Apparently, the tumor growth rate in the mice injected with U251-pBabe-JARID1B cells was greater than that in the control mice and this was confirmed by measuring the mean tumor volume 42 days after injection (Fig. 7C). Furthermore, JARID1B expression in the xenograft was confirmed by immunohistochemical analysis (Fig. 7D). Figure 7 Jumonji AT-rich interactive domain 1B (JARID1B) promotes tumorigenesis in glioma cells and and enhanced glioma tumorigenesis in vivo. Taken together, these findings suggest that JARID1B is potentially an important molecular target for the design of novel anti-glioma therapies. Acknowledgments The present study was supported by a grant from the National Natural Science Foundation of China (no. 81301168)..

Leave a Reply

Your email address will not be published.